This January, Vericiguat (VERQUVO) received approval by FDA as a drug for patients who have symptomatic, chronic heart failure with reduced ejection fraction (HFrEF).
It targets cyclic guanosine monophosphate (cGMP), as a means to lower the risk of cardiovascular events in high-risk patients. Vericiguat stimulates soluble guanylate cyclase (sGC) to produce cGMP and restore nitric oxide sensitivity. By increasing cGMP production, Vericiguat decreases arterial constriction and arterial stiffness.
This drug contains 1H-pyrazolo[3,4-b]pyridine moiety in its backbone.
We have made a set of Building Blocks, which contain such part – the perfect start for your research!